Prognostic Evaluation of VEGFA Genotypes and Haplotypes in a Cohort of Brazilian Women with Non Metastatic Breast Cancer

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2016 May 20

PMID 27195611

Citations 5

Authors

Hayra de Andrade Vieira-Monteiro

Daniely Regina Freitas-Alves

Marcelo Sobral-Leite

Joao Marcos de Azevedo Delou

Sheyla Maria Torres Goulart-Citrangulo

Camila Telles do Nascimento

Thales Nascimento E Castro

Sergio Koifman

Jamila Alessandra Perini

Rosane Vianna-Jorge

Affiliations

Soon will be listed here.

Abstract

Vascular Endothelial Growth Factor (VEGF) mediates angiogenesis, which is crucial for tumor development and progression. The present study aimed to evaluate the impact of VEGFA gene polymorphisms rs699947, rs833061, rs1570360, rs2010963 and rs3025039 on breast cancer features and prognosis. A cohort of Brazilian women (N = 1038) with unilateral non-metastatic breast cancer was evaluated. The association between VEGFA polymorphisms and histopathological features or pathological complete response (pCR) to neoadjuvant chemotherapy was evaluated by the Chi-square test, with calculation of the respective odds ratio (OR) and 95% confidence intervals (95% CI). The impact of individual categories on disease-free survival was evaluated using Kaplan-Meier curves and multivariate Cox proportional hazards regression models for calculation of adjusted hazard ratios (HRadjusted). Variant genotypes of rs699947 (CA + AA) were significantly associated with high-grade (G2 + G3) tumors (OR = 1.82; 95% CI = 1.15 - 2.89), and with shorter disease-free survival among patients treated with neoadjuvant chemotherapy followed by mastectomy (HRadjusted = 1.82; 95% CI = 1.16 - 2.86). Variant genotypes of rs833061 (TC + CC) were significantly associated with high-grade (G2 + G3) tumors (OR = 1.79; 95% CI = 1.12 - 2.84) and with positive lymph node status (OR = 1.34; 95% CI = 1.01 - 1.77), but showed no independent effect on disease-free survival. Variant haplotypes (*2 to *5) appear to favor pCR (OR = 7.1; 95% CI = 1.7 - 30.1). VEGFA genotyping may add to prognostic evaluation of breast cancer, with rs699947 being the most likely to contribute.

Citing Articles

Euterpe oleracea extract inhibits tumorigenesis effect of the chemical carcinogen DMBA in breast experimental cancer.

Alessandra-Perini J, Perini J, Rodrigues-Baptista K, de Moura R, Junior A, Dos Santos T BMC Complement Altern Med. 2018; 18(1):116.

PMID: 29609579 PMC: 5879811. DOI: 10.1186/s12906-018-2183-z.

Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.

Sobral-Leite M, Lips E, Vieira-Monteiro H, Giacomin L, Freitas-Alves D, Cornelissen S PLoS One. 2017; 12(12):e0189750.

PMID: 29267323 PMC: 5739423. DOI: 10.1371/journal.pone.0189750.

Clinical significance and prospective molecular mechanism of MALAT1 in pancreatic cancer exploration: a comprehensive study based on the GeneChip, GEO, Oncomine, and TCGA databases.

Xie Z, Dang Y, Wei D, Chen P, Tang R, Huang Q Onco Targets Ther. 2017; 10:3991-4005.

PMID: 28860807 PMC: 5558580. DOI: 10.2147/OTT.S136878.

Loss of constitutive expression in breast cancer associated with worse prognosis.

Delou J, Vignal G, Indio-do-Brasil V, de Souza Accioly M, Lopes da Silva T, Piranda D Breast Cancer (Dove Med Press). 2017; 9:415-428.

PMID: 28670140 PMC: 5479298. DOI: 10.2147/BCTT.S131284.

A Comparative Approach of Tumor-Associated Inflammation in Mammary Cancer between Humans and Dogs.

Carvalho M, Silva-Carvalho R, Pires I, Prada J, Bianchini R, Jensen-Jarolim E Biomed Res Int. 2017; 2016:4917387.

PMID: 28053982 PMC: 5178344. DOI: 10.1155/2016/4917387.

References

Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R . Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 2005; 11(10):3647-53. DOI: 10.1158/1078-0432.CCR-04-1803. View

Balasubramanian S, Cox A, Cross S, Higham S, Brown N, Reed M . Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer. 2007; 121(5):1009-16. DOI: 10.1002/ijc.22772. View

Jacobs E, Feigelson H, Bain E, Brady K, Rodriguez C, Stevens V . Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006; 8(2):R22. PMC: 1557725. DOI: 10.1186/bcr1400. View

Rahoui J, Laraqui A, Sbitti Y, Touil N, Ibrahimi A, Ghrab B . Investigating the association of vascular endothelial growth factor polymorphisms with breast cancer: a Moroccan case-control study. Med Oncol. 2014; 31(9):193. DOI: 10.1007/s12032-014-0193-3. View

Gasparini G . Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000; 5 Suppl 1:37-44. DOI: 10.1634/theoncologist.5-suppl_1-37. View

Maae E, Andersen R, Steffensen K, Jakobsen E, Brandslund I, Sorensen F . Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer. Anticancer Res. 2012; 32(9):3619-27. View

Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K . A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002; 51(5):1635-9. DOI: 10.2337/diabetes.51.5.1635. View

Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K . Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation. 1999; 100(5):547-52. DOI: 10.1161/01.cir.100.5.547. View

Absenger G, Szkandera J, Stotz M, Pichler M, Winder T, Langsenlehner T . A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer. Mol Carcinog. 2013; 52 Suppl 1:E96-102. DOI: 10.1002/mc.22028. View

10.

Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P . The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat. 2012; 133(2):769-78. DOI: 10.1007/s10549-012-1980-1. View

11.

Yan Y, Liang H, Li T, Guo S, Li M, Li S . Vascular endothelial growth factor +936C/T polymorphism and breast cancer risk: a meta-analysis of 13 case-control studies. Tumour Biol. 2014; 35(3):2687-92. PMC: 3967057. DOI: 10.1007/s13277-013-1354-2. View

12.

Sa-Nguanraksa D, Chuangsuwanich T, Pongpruttipan T, Kummalue T, Rojananin S, Ratanawichhitrasin A . Vascular endothelial growth factor ‑634G/C polymorphism is associated with increased breast cancer risk and aggressiveness. Mol Med Rep. 2013; 8(4):1242-50. DOI: 10.3892/mmr.2013.1607. View

13.

Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm D . Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 2010; 124(1):133-40. DOI: 10.1007/s10549-010-1103-9. View

14.

Dorjgochoo T, Zheng Y, Gao Y, Ma X, Long J, Bao P . No association between genetic variants in angiogenesis and inflammation pathway genes and breast cancer survival among Chinese women. Cancer Epidemiol. 2013; 37(5):619-24. PMC: 4064366. DOI: 10.1016/j.canep.2013.06.005. View

15.

Luo T, Chen L, He P, Hu Q, Zhong X, Sun Y . Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in a Chinese population. Asian Pac J Cancer Prev. 2013; 14(4):2433-7. DOI: 10.7314/apjcp.2013.14.4.2433. View

16.

Wehrschuetz M, Schollnast H, Wehrschuetz E, Renner W, Luschin G . VEGF 936C > T Polymorphism and Association of BI-RADS Score in Women with Suspected Breast Cancer. Breast Cancer (Auckl). 2011; 3:77-81. PMC: 3086306. DOI: 10.4137/bcbcr.s3164. View

17.

Danova M, Delfanti S, Manzoni M, Mariucci S . Tissue and soluble biomarkers in breast cancer and their applications: ready to use?. J Natl Cancer Inst Monogr. 2011; 2011(43):75-8. DOI: 10.1093/jncimonographs/lgr023. View

18.

Slattery M, John E, Torres-Mejia G, Lundgreen A, Lewinger J, Stern M . Angiogenesis genes, dietary oxidative balance and breast cancer risk and progression: the Breast Cancer Health Disparities Study. Int J Cancer. 2013; 134(3):629-44. PMC: 3830596. DOI: 10.1002/ijc.28377. View

19.

Kapahi R, Guleria K, Sambyal V, Manjari M, Sudan M, Uppal M . Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in Punjabi population from North West India. Tumour Biol. 2014; 35(11):11171-81. DOI: 10.1007/s13277-014-2404-0. View

20.

Soerjomataram I, Louwman M, Ribot J, Roukema J, Coebergh J . An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2007; 107(3):309-30. PMC: 2217620. DOI: 10.1007/s10549-007-9556-1. View